Is It Too Late to Buy Eli Lilly Stock Now?
Eli Lilly (NYSE: LLY) is the largest healthcare company in the world by market capitalization. With dividends reinvested, the company's stock is up an eye-popping 1,530% over the past 10 years.
But over the last year, in particular, Lilly's stock has enjoyed an unprecedented run, fueled by interest in the weight-loss market. Following is a deep dive into Lilly's position in diabetes and obesity and a look at whether the company has enough catalysts outside these markets to keep up its momentum.
The weight-loss market is currently being disrupted by a class of medications called glucagon-like peptide-1 (GLP-1). Popular GLP-1 treatments include Ozempic, Wegovy, and Rybelsus -- all of which are produced by Lilly's Danish rival, Novo Nordisk.
Source Fool.com
Popular Inc. Stock
With 9 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 96 € there is a slightly positive potential of 16.36% for Popular Inc. compared to the current price of 82.5 €.
